Simulations Plus Inc
NASDAQ:SLP

Watchlist Manager
Simulations Plus Inc Logo
Simulations Plus Inc
NASDAQ:SLP
Watchlist
Price: 31.32 USD 4.26% Market Closed
Market Cap: 628.6m USD
Have any thoughts about
Simulations Plus Inc?
Write Note

Simulations Plus Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Simulations Plus Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Simulations Plus Inc
NASDAQ:SLP
Income from Continuing Operations
$10m
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
13%
Veeva Systems Inc
NYSE:VEEV
Income from Continuing Operations
$615.3m
CAGR 3-Years
13%
CAGR 5-Years
16%
CAGR 10-Years
35%
Inspire Medical Systems Inc
NYSE:INSP
Income from Continuing Operations
$33m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Doximity Inc
NYSE:DOCS
Income from Continuing Operations
$147.6m
CAGR 3-Years
43%
CAGR 5-Years
80%
CAGR 10-Years
N/A
Omnicell Inc
NASDAQ:OMCL
Income from Continuing Operations
-$17.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
Waystar Holding Corp
NASDAQ:WAY
Income from Continuing Operations
-$51.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Simulations Plus Inc
Glance View

Market Cap
628m USD
Industry
Health Care

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The company is headquartered in Lancaster, California and currently employs 135 full-time employees. The company provides prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology. The company also provides consulting services ranging from early drug discovery through preclinical and clinical trial development to regulatory submissions in support of product approval. The company offers 11 software products for pharmaceutical research and development, which includes GastroPlus, DDDPlus, MembranePlus, DILIsym, NAFLDsym, ADMET Predictor, MedChem Designer, MedChem Studio, PKPlus, KIWI and Monolix Suite of products through Lixoft. Its software and consulting services are provided to pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies and to academic and regulatory agencies worldwide for use in the conduct of industry-based research. Cognigen Corporation, DILIsym Services, Inc. and Lixoft are its subsidiaries.

SLP Intrinsic Value
20.55 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Simulations Plus Inc's Income from Continuing Operations?
Income from Continuing Operations
10m USD

Based on the financial report for Aug 31, 2024, Simulations Plus Inc's Income from Continuing Operations amounts to 10m USD.

What is Simulations Plus Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
13%

Over the last year, the Income from Continuing Operations growth was 0%. The average annual Income from Continuing Operations growth rates for Simulations Plus Inc have been 1% over the past three years , 3% over the past five years , and 13% over the past ten years .

Back to Top